The CHMP has recommended the approval of AbbVie's upadacitinib (Rinvoq) for treating adults with giant cell arteritis (GCA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback